Eukaryotic Initiation Factor 6 (EIF6) is a conserved protein involved in ribosome biogenesis and translation regulation. It binds to the 60S ribosomal subunit, preventing premature interaction with the 40S subunit during assembly. EIF6 also plays roles in cellular processes like cell proliferation, metabolism, and stress responses, with dysregulation linked to cancers, diabetes, and developmental disorders. EIF6 antibodies are essential tools for studying its expression, localization, and function. These antibodies are widely used in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to detect EIF6 levels in tissues or cultured cells. Researchers employ them to investigate EIF6's oncogenic potential, as its overexpression correlates with tumor growth and poor prognosis in cancers like breast, colorectal, and hepatocellular carcinoma. Both monoclonal and polyclonal EIF6 antibodies are available, often validated for specificity through knockout cell lines or siRNA knockdown. Commercial EIF6 antibodies are typically raised in rabbits or mice against conserved regions of the protein. Recent studies also explore EIF6's role in mTOR signaling and metabolic reprogramming, expanding its relevance in therapeutic targeting. Proper antibody validation remains critical due to potential cross-reactivity with structurally similar proteins.